Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 35,100 KRW
Change Today -300.00 / -0.85%
Volume 11.9K
086450 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 2:10 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

dongkook pharmaceutical co l (086450) Snapshot

Open
35,400
Previous Close
35,400
Day High
35,500
Day Low
34,750
52 Week High
10/21/14 - 47,000
52 Week Low
06/13/14 - 24,500
Market Cap
312.1B
Average Volume 10 Days
21.6K
EPS TTM
2,390
Shares Outstanding
8.9M
EX-Date
12/29/14
P/E TM
14.7x
Dividend
300.00
Dividend Yield
0.85%
Current Stock Chart for DONGKOOK PHARMACEUTICAL CO L (086450)

Related News

No related news articles were found.

dongkook pharmaceutical co l (086450) Related Businessweek News

No Related Businessweek News Found

dongkook pharmaceutical co l (086450) Details

DONGKOOK Pharmaceutical Co., Ltd. offers pharmaceutical products in South Korea. Its products include Sodium Hyaluronate injection for defornative osteoarthritis of the knees and periathritis of the shoulder; Gadopentetate Dimeglumine injection for contrasr enhancement during cranial and spinal MRI investigations; Octrin LAR injection for acromegaly, carcinoidtumors, and vasoactive intestinal peptide tumors; and Iopamidol injection for use as an X-ray contrast media for neuroradiology, angiography, urography, and computer tomography. The company’s products also comprise Triptorelin Depot injection for prostatic carcinoma, the management of advanced prostatic carcinoma, and fenital and extragenital endometriosis; Pofol injection, an intravenous anesthetic for induction and maintenance of general anesthesia and sedation of ventilated patients receiving intensive care; and Teicoplanin injection for skin and soft tissue infections, urinary and lower respiratory tract infections, joint and bone infections, septicaemia, endocarditis, and peritonitis related to continuous ambulatory peritoneal dialysis. In addition, it offers Streptokinase injection for the therapeutic indication of acute myocardial infarction, acute massive pulmonary embolism, acute deep vein thrombosis, acute arterial thrombosis and embolism, and occluded arteriovenous cannulae; Leuprorelin acetate injection for the treatment of prostatic cancer, endometriosis, premenopausal breast cancer, and central precocious puberty, as well as reduction of myoma nucleus and improvement of symptom in uterine myoma; and Alprostadil injection for chronic arteriosclerosis and skin ulcers. Further, the company provides raw material medicines. It also exports its products. The company was formerly known as UEC & Co., Ltd. DONGKOOK Pharmaceutical Co., Ltd. was founded in 1968 and is based in Seoul, South Korea.

Founded in 1968

dongkook pharmaceutical co l (086450) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

dongkook pharmaceutical co l (086450) Key Developments

DONGKOOK Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015

DONGKOOK Pharmaceutical Co., Ltd., Annual General Meeting, Mar 20, 2015., at 10:00 Korea Standard Time. Location: Auditorium Building B1. Agenda: To consider approval of financial statements for the year ended December 31, 2014; to consider appointment of directors; and to consider approval of the remuneration.

Probi Announces Distribution Agreement with Dongkook Pharmaceutical

Probi has signed a distribution agreement with Dongkook Pharmaceutical Co., Ltd. for the distribution of Probi's gut health product, Probi Mage®. The Product will be launched under Probi's brand in South Korea in the second quarter of 2014. Dongkook will launch Probi Mage® as a dietary supplement in department stores and TV/Internet home shopping.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
086450:KS 35,100.00 KRW -300.00

086450 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 086450.
View Industry Companies
 

Industry Analysis

086450

Industry Average

Valuation 086450 Industry Range
Price/Earnings 14.4x
Price/Sales 1.3x
Price/Book 1.7x
Price/Cash Flow 14.3x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DONGKOOK PHARMACEUTICAL CO L, please visit www.dkpharm.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.